[go: up one dir, main page]

NO20042601L - Ny peptid med angiotensinkonvertasehemmende effekt - Google Patents

Ny peptid med angiotensinkonvertasehemmende effekt

Info

Publication number
NO20042601L
NO20042601L NO20042601A NO20042601A NO20042601L NO 20042601 L NO20042601 L NO 20042601L NO 20042601 A NO20042601 A NO 20042601A NO 20042601 A NO20042601 A NO 20042601A NO 20042601 L NO20042601 L NO 20042601L
Authority
NO
Norway
Prior art keywords
inhibitory effect
new peptide
angiotensin convertase
convertase inhibitory
angiotensin
Prior art date
Application number
NO20042601A
Other languages
English (en)
Other versions
NO328611B1 (no
Inventor
Hiroshi Miyakawa
Akio Yamada
Yoshitaka Tamura
Hiroshi Ochi
Hitoshi Saito
Yasushi Kawaguchi
Tomoko Ide
Eri Inoue
Original Assignee
Morinaga Milk Industry Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19167543&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20042601(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Morinaga Milk Industry Co Ltd filed Critical Morinaga Milk Industry Co Ltd
Publication of NO20042601L publication Critical patent/NO20042601L/no
Publication of NO328611B1 publication Critical patent/NO328611B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4732—Casein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Et peptid Met-Lys-Pro som er oppnådd ved kjemisk syntese eller hydrolyse av kasein, blir benyttet som aktiv ingrediens av angiotensinomdannende enzymbemmere eller hypotensive stoffer.
NO20042601A 2001-11-21 2004-06-21 Nytt peptid med angiotensinkonvertasehemmende effekt NO328611B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001355923 2001-11-21
PCT/JP2002/012197 WO2003044044A1 (en) 2001-11-21 2002-11-21 Novel peptide having angiotensin convertase inhibitory effect

Publications (2)

Publication Number Publication Date
NO20042601L true NO20042601L (no) 2004-08-18
NO328611B1 NO328611B1 (no) 2010-03-29

Family

ID=19167543

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042601A NO328611B1 (no) 2001-11-21 2004-06-21 Nytt peptid med angiotensinkonvertasehemmende effekt

Country Status (18)

Country Link
US (1) US7022676B2 (no)
EP (1) EP1457498B9 (no)
JP (1) JP3816921B2 (no)
KR (1) KR100615844B1 (no)
CN (1) CN1240711C (no)
AT (1) ATE353336T1 (no)
AU (1) AU2002366037B2 (no)
BR (1) BR0214299A (no)
CA (1) CA2468039C (no)
CY (1) CY1106557T1 (no)
DE (1) DE60218064T2 (no)
DK (1) DK1457498T3 (no)
ES (1) ES2281567T3 (no)
MX (1) MXPA04004805A (no)
NO (1) NO328611B1 (no)
NZ (1) NZ533544A (no)
PT (1) PT1457498E (no)
WO (1) WO2003044044A1 (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101174299B1 (ko) 2003-08-01 2012-08-16 칼피스가부시키가이샤 카세인 가수분해물, 그 제조법 및 그 용도
WO2005061529A1 (ja) * 2003-12-01 2005-07-07 Meiji Dairies Corporation アンジオテンシン変換酵素阻害ペプチド
CN102304169B (zh) * 2011-08-05 2013-03-20 成都中医药大学 降血压多肽及其用途
CN102276690B (zh) * 2011-08-05 2013-03-20 成都中医药大学 降血压功能性多肽及其用途
JP5926363B2 (ja) * 2012-02-22 2016-05-25 森永乳業株式会社 ジペプチジルペプチダーゼ−ｉｖ阻害剤
CN104159912B (zh) 2012-03-09 2016-11-09 森永乳业株式会社 二肽基肽酶iv 抑制剂
US9345727B2 (en) 2013-03-15 2016-05-24 Mead Johnson Nutrition Company Nutritional compositions containing a peptide component and uses thereof
US9289461B2 (en) 2013-03-15 2016-03-22 Mead Johnson Nutrition Company Reducing the risk of autoimmune disease
US9138455B2 (en) 2013-03-15 2015-09-22 Mead Johnson Nutrition Company Activating adiponectin by casein hydrolysate
US9345741B2 (en) 2013-03-15 2016-05-24 Mead Johnson Nutrition Company Nutritional composition containing a peptide component with adiponectin simulating properties and uses thereof
US8889633B2 (en) 2013-03-15 2014-11-18 Mead Johnson Nutrition Company Nutritional compositions containing a peptide component with anti-inflammatory properties and uses thereof
US9352020B2 (en) 2013-03-15 2016-05-31 Mead Johnson Nutrition Company Reducing proinflammatory response
JP6344796B2 (ja) * 2014-09-30 2018-06-20 森永乳業株式会社 高齢者用アルツハイマー型認知症改善剤
JP2018057346A (ja) * 2016-10-07 2018-04-12 森永乳業株式会社 カゼイン酵素処理物及びその製造方法
CN107337710A (zh) * 2017-07-26 2017-11-10 盐城卫生职业技术学院 一种抗高血压活性肽The‑The‑Pro及应用和药物组合物
US20230158098A1 (en) 2017-09-19 2023-05-25 Morinaga Milk Industry Co., Ltd. Composition for promoting energy expenditure
WO2019160024A1 (ja) 2018-02-16 2019-08-22 森永乳業株式会社 血圧降下用及び／又は中性脂肪低減用の組成物
JP2019142791A (ja) * 2018-02-16 2019-08-29 森永乳業株式会社 血圧降下用及び／又は中性脂肪低減用の組成物
JP6589011B2 (ja) * 2018-05-17 2019-10-09 森永乳業株式会社 脳機能障害改善用経口組成物
CN113321719B (zh) * 2021-05-20 2022-03-18 澳优乳业（中国）有限公司 一种寡肽及其制备方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07313185A (ja) * 1992-08-20 1995-12-05 Marino Forum 21 ぺプチドの製造方法
JP3040389B2 (ja) * 1999-01-18 2000-05-15 日本合成化学工業株式会社 ペプチドの製造法

Also Published As

Publication number Publication date
NO328611B1 (no) 2010-03-29
AU2002366037A1 (en) 2003-06-10
CN1612892A (zh) 2005-05-04
CA2468039C (en) 2011-01-04
HK1076114A1 (en) 2006-01-06
AU2002366037B2 (en) 2005-11-03
DE60218064T2 (de) 2007-11-15
JP3816921B2 (ja) 2006-08-30
KR20050044541A (ko) 2005-05-12
US7022676B2 (en) 2006-04-04
CN1240711C (zh) 2006-02-08
ATE353336T1 (de) 2007-02-15
EP1457498A4 (en) 2005-10-19
BR0214299A (pt) 2004-12-14
EP1457498B9 (en) 2009-09-02
US20050004041A1 (en) 2005-01-06
DK1457498T3 (da) 2007-06-04
ES2281567T3 (es) 2007-10-01
EP1457498A1 (en) 2004-09-15
KR100615844B1 (ko) 2006-08-25
CA2468039A1 (en) 2003-05-30
EP1457498B1 (en) 2007-02-07
CY1106557T1 (el) 2012-01-25
JPWO2003044044A1 (ja) 2005-03-10
PT1457498E (pt) 2007-05-31
NZ533544A (en) 2005-02-25
DE60218064D1 (de) 2007-03-22
WO2003044044A1 (en) 2003-05-30
MXPA04004805A (es) 2004-08-11

Similar Documents

Publication Publication Date Title
NO20042601L (no) Ny peptid med angiotensinkonvertasehemmende effekt
ATE354687T1 (de) Verwendung von unter atmosphärischem druck erzeugten dichten plasmen zur behandlung von abgasen
BR9908280A (pt) Inibidores de enzimas de fosfolipase
ES2172303T3 (es) Agentes terapeuticos obtenidos por catalisis enzimatica.
DE60330376D1 (de) Defructosylierungsverfahren
MXPA05011784A (es) Producto de caseina hidrolizada que comprende tripeptidos isoleucina-prolina-prolina y/o valina-prolina-prolina.
TR200003028T2 (tr) Yeni ikame edilmiş amidler, bunların üretimi ve kullanımı.
TR199902751T2 (xx) Proteaz inhibit�rleri.
EA200700215A1 (ru) Протеиновые гидролизаты, снижающие давление крови
ATE335485T1 (de) Quinolin-enthaltende alpha-ketoamid-basierte inhibitoren von cystein- und serin protease
ATE309264T1 (de) Peptidyl-2-amino-1hydroxyalkansulfonsäuren als cystein-protease-inhibitoren
BR0313969A (pt) Inibidores de oxitocina
ATE343369T1 (de) Neue verwendung von proteinhydrolysaten
ATE382604T1 (de) Aminosäure-derivate als hiv aspartyl-protease- inhibitoren
NO984344L (no) Ny asymmetriske syntese av R-<alfa>-propylpiperonyalamin og dets analoger
WO2004002539A8 (en) Sealant or tissue generating product comprising a plasma matrix and growth factors
DK0804410T3 (da) Fremgangsmåde til fremstilling af retrovirale proteaseinhibitor-mellemprodukter
NO20016151L (no) Fremstilling av substituerte piperidin-4-oner
WO2004104030A3 (fr) Peptides modulateurs de l'activite du facteur de transcription engrailed
AU2003203028A1 (en) Aggrecanase-1 and -2 peptide substrates and methods
MXPA02012030A (es) Sustratos peptidicos de metalorpoteasas y metodos.
WO2004024765A8 (en) Crystal structure of an angiotensin-converting enzyme (ace) and uses thereof
NO20044769L (no) Behandling av smerte med ifendropil
NO20054172L (no) Nye blandinger
DK1096951T3 (da) Anvendelse af bromelainproteaser til inhiberingen af blodkoaguleringen

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees